Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06638931
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:54.670794+00:00
Published At
2026-04-15T00:00:00+00:00
Record Updated At
2026-04-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Urachal Cancer", "Parathyroid Carcinoma", "Fibrolamellar Carcinoma", "Angiosarcoma", "Secretory Carcinoma of Breast", "Anal Neoplasms", "Metaplastic Breast Carcinoma", "Translocation Renal Cell Carcinoma", "Carcinosarcoma", "Small Intestine Neoplasms", "Cholangiocarcinoma", "Sertoli-Leydig Cell Tumor", "Adenoid Cystic Carcinoma", "Mesothelioma", "Neuroblastoma", "Adrenal Gland Neoplasms", "Penile Neoplasms", "Apocrine Carcinoma", "Fibrosarcoma", "Cancer of Unknown Primary", "Hemangioblastoma", "Thyroid Neoplasms", "Hepatoblastoma", "Fallopian Tube Neoplasms", "Leiomyosarcoma", "Vaginal Neoplasms", "Neurofibrosarcoma", "Gallbladder Neoplasms", "Osteosarcoma", "Biliary Tract Neoplasms", "Clear Cell Endometrial Cancer", "Yolk Sac Tumor", "Vulvar Neoplasms", "Kaposi Sarcoma", "Ovarian Epithelial Cancer", "Soft Tissue Sarcoma", "Urethral Neoplasms", "Granulosa Cell Tumor", "Primitive Neuroectodermal Tumor", "Neuroendocrine Tumors", "Trophoblastic Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-15"
protocolSection.identificationModule.nctId
"NCT06638931"
protocolSection.identificationModule.officialTitle
"Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Urachal Cancer (protocolSection.conditionsModule.conditions)
  • Parathyroid Carcinoma (protocolSection.conditionsModule.conditions)
  • Fibrolamellar Carcinoma (protocolSection.conditionsModule.conditions)
  • Angiosarcoma (protocolSection.conditionsModule.conditions)
  • Secretory Carcinoma of Breast (protocolSection.conditionsModule.conditions)
  • Anal Neoplasms (protocolSection.conditionsModule.conditions)
  • Metaplastic Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Translocation Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Small Intestine Neoplasms (protocolSection.conditionsModule.conditions)
  • Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
  • Sertoli-Leydig Cell Tumor (protocolSection.conditionsModule.conditions)
  • Adenoid Cystic Carcinoma (protocolSection.conditionsModule.conditions)
  • Mesothelioma (protocolSection.conditionsModule.conditions)
  • Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Adrenal Gland Neoplasms (protocolSection.conditionsModule.conditions)
  • Penile Neoplasms (protocolSection.conditionsModule.conditions)
  • Apocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Fibrosarcoma (protocolSection.conditionsModule.conditions)
  • Cancer of Unknown Primary (protocolSection.conditionsModule.conditions)
  • Hemangioblastoma (protocolSection.conditionsModule.conditions)
  • Thyroid Neoplasms (protocolSection.conditionsModule.conditions)
  • Hepatoblastoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Neoplasms (protocolSection.conditionsModule.conditions)
  • Leiomyosarcoma (protocolSection.conditionsModule.conditions)
  • Vaginal Neoplasms (protocolSection.conditionsModule.conditions)
  • Neurofibrosarcoma (protocolSection.conditionsModule.conditions)
  • Gallbladder Neoplasms (protocolSection.conditionsModule.conditions)
  • Osteosarcoma (protocolSection.conditionsModule.conditions)
  • Biliary Tract Neoplasms (protocolSection.conditionsModule.conditions)
  • Clear Cell Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Yolk Sac Tumor (protocolSection.conditionsModule.conditions)
  • Vulvar Neoplasms (protocolSection.conditionsModule.conditions)
  • Kaposi Sarcoma (protocolSection.conditionsModule.conditions)
  • Ovarian Epithelial Cancer (protocolSection.conditionsModule.conditions)
  • Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Urethral Neoplasms (protocolSection.conditionsModule.conditions)
  • Granulosa Cell Tumor (protocolSection.conditionsModule.conditions)
  • Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Tumors (protocolSection.conditionsModule.conditions)
  • Trophoblastic Tumor (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.